A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Ydreborg, Magdalena ^a   Lisovskaja, Vera ^b   Lagging, Martin ^a   Christensen, Peer Brehm ^c   Langeland, Nina ^d   Buhl, Mads Rauning ^e   Pedersen, Court ^c   Mørch, Kristine ^d   Wejstål, Rune ^a   Norkrans, Gunnar ^a   Lindh, Magnus ^a   Färkkilä, Martti ^f   Westin, Johan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF BERGEN   (Norway)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; LATHOSTEROL; PROTHROMBIN; STEROL;

ABSORPTION; ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL SYNTHESIS; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; EXPLORATORY RESEARCH; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORDIC LIVER INDEX; OUTCOME VARIABLE; PATIENT REFERRAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; VALIDATION STUDY;

BIOLOGICAL MARKERS; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; STEROLS;

EID: 84899420336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093601     Document Type: Article

References (46)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472. (Pubitemid 27078833)
2. (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.
3. Perrault J, McGill DB, Ott BJ, Taylor WF (1978) Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74: 103-106. (Pubitemid 8248893)
4. (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20: 15-20.
5. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457. (Pubitemid 37466971)
6. Pohl A, Behling C, Oliver D, Kilani M, Monson P, et al. (2001) Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96: 3142-3146. (Pubitemid 33095354)
7. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, et al. (2005) A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42: 1373-1381. (Pubitemid 43260040)
8. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, et al. (2008) Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47: 789-798. (Pubitemid 351449670)
9. Poynard T, Bedossa P (1997) Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4: 199-208. (Pubitemid 127733511)
10. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, et al. (2005) Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 42: 282-292. (Pubitemid 41061080)
11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526. (Pubitemid 36919874)
12. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, et al. (2005) Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51: 1867-1873. (Pubitemid 41368177)
13. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713. (Pubitemid 39575849)
14. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, et al. (2010) Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 53: 1013-1021.
15. Islam S, Antonsson L, Westin J, Lagging M (2005) Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 40: 867-872. (Pubitemid 40978865)
16. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36. (Pubitemid 47171918)
17. Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.
18. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, et al. (2006) Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44: 1511-1517. (Pubitemid 44953656)
19. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, et al. (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41: 48-54. (Pubitemid 40066382)
20. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134: 960-974.
21. Castera L, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, et al. (2009) Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 50: 59-68.
22. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, et al. (2011) A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 106: 1255-1263.
23. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, et al. (2009) SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 49: 1821-1827.
24. Bjorkhem I, Miettinen T, Reihner E, Ewerth S, Angelin B, et al. (1987) Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 28: 1137-1143. (Pubitemid 17151579)
25. Miettinen TA, Tilvis RS, Kesaniemi YA (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131: 20-31. (Pubitemid 20014696)
26. Nikkila K, Hockerstedt K, Miettinen TA (1991) High cholestanol and low campesterol-to-sitosterol ratio in serum of patients with primary biliary cirrhosis before liver transplantation. Hepatology 13: 663-669.
27. Nikkila K, Hockerstedt K, Miettinen TA (1992) Serum and hepatic cholestanol, squalene and noncholesterol sterols in man: a study on liver transplantation. Hepatology 15: 863-870.
28. Nikkila K, Miettinen TA, Hockerstedt KV, Isoniemi H (2005) Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 18: 221-225. (Pubitemid 41743314)
29. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47: 1837-1845. (Pubitemid 351945551)
30. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29: 1705-1713. (Pubitemid 38091720)
31. Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29: 43-51.
32. Gylling H, Hallikainen M, Simonen P, Miettinen HE, Nissinen MJ, et al. (2012) Serum and lipoprotein sitostanol and non-cholesterol sterols after an acute dose of plant stanol ester on its long-term consumption. Eur J Nutr 51: 615-622.
33. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
34. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R (2002) Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37: 837-842. (Pubitemid 35404224)
35. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, et al. (2001) Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 113: 590-595. (Pubitemid 32524375)
36. Nikkila K, Nissinen MJ, Gylling H, Isoniemi H, Miettinen TA (2008) Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation. J Hepatol 49: 936-945.
37. Negro F (2010) Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 59: 1279-1287.
38. Kumar D, Farrell GC, Fung C, George J (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36: 1266-1272. (Pubitemid 35253445)
39. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38: 75-85. (Pubitemid 36775798)
40. Cua IH, Hui JM, Kench JG, George J (2008) Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 48: 723-731.
41. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, et al. (2006) Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43: 64-71. (Pubitemid 43738959)
42. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, et al. (2012) Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56: 49-56.
43. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, et al. (2006) Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 44: 925-935. (Pubitemid 46489557)
44. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075. (Pubitemid 32322537)
45. Parkes J, Guha IN, Roderick P, Harris S, Cross R, et al. (2011) Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 18: 23-31.
46. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832. (Pubitemid 27129209)